Skip to main content
Top
Published in: Comparative Clinical Pathology 1/2016

01-01-2016 | Original Article

Efficacy and safety of a biogeneric recombinant human erythropoietin in the management of chemotherapy-induced anemia: a randomized double-blind active-comparator trial

Authors: Yunes Panahi, Alireza Saadat, Saber Imani, Amirhossein Sahebkar

Published in: Comparative Clinical Pathology | Issue 1/2016

Login to get access

Abstract

Anemia is a common complication of chemotherapy, and its presence affects the quality of life of cancer patients. Recombinant human erythropitein (rHuEPO) is the mainstay of treatment in patients suffering from chemotherapy-induced anemia. Since rHuEPO is a costly treatment, development of biogeneric products with equivalent efficacy and safety is an essential requirement. This study aimed to compare the efficacy and safety of a biogeneric rHuEPO (Epolyrec®) with those of the original brand-name product (Eprex®). Seventy-seven cancer patients with hemoglobin levels <11 g/dL, serum ferritin >100 ng/dL, and a life expectancy of at least 6 months were recruited into the trial. Included subjects were randomly assigned to either Epolyrec® (n = 37) or Eprex® (n = 40) at a weekly dose of 100 IU/kg (divided in three doses), for a period of 8 weeks. Hemoglobin and hematocrit levels were significantly increased by week 4 in the Epolyrec® group (p < 0.001), while remained statistically constant from weeks 4 to 8. In the Eprex® group, increases in hemoglobin levels did not reach significance by week 4, but the values at week 8 were significantly increased (p = 0.001). In spite of increase, no significant change in hematocrit values was observed in the Eprex® group. Comparison of the magnitude of changes in hemoglobin concentrations between the study groups revealed a significantly greater increase from baseline to week 4 in the Epolyrec® group (p = 0.02), while the change from week 4 to week 8 was greater in the Eprex® group (p = 0.005). As to hematocrit values, the magnitude of changes at both study periods was comparable between the study groups (p > 0.05). There was no report of severe adverse events in either of the study groups. The present findings support equivalent efficacy and safety of Epolyrec® and Eprex® in the management of chemotherapy-induced anemia.
Literature
go back to reference Beiraghdar F, Panahi Y, Einollahi B, Torkaman M, Mohammadi R, Marzony ET, Sahebkar A (2012a) Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the correction of post-transplantation anemia: a randomized comparative trial with Eprex. Clin Lab 58(11-12):1179–1185PubMed Beiraghdar F, Panahi Y, Einollahi B, Torkaman M, Mohammadi R, Marzony ET, Sahebkar A (2012a) Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the correction of post-transplantation anemia: a randomized comparative trial with Eprex. Clin Lab 58(11-12):1179–1185PubMed
go back to reference Beiraghdar F, Panahi Y, Einollahi B, Nemati E, Ghadiani MH, Sahebkar A, Maghsoudi N, Marzony ET (2012b) Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial. Clin Lab 58(7-8):737–745PubMed Beiraghdar F, Panahi Y, Einollahi B, Nemati E, Ghadiani MH, Sahebkar A, Maghsoudi N, Marzony ET (2012b) Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial. Clin Lab 58(7-8):737–745PubMed
go back to reference Bennett CL, Spiegel DM, Macdougall IC, Norris L, Qureshi ZP, Sartor O, Lai SY, Tallman MS, Raisch DW, Smith SW, Silver S, Murday AS, Armitage JO, Goldsmith D (2012) A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 38(8):783–796CrossRefPubMedPubMedCentral Bennett CL, Spiegel DM, Macdougall IC, Norris L, Qureshi ZP, Sartor O, Lai SY, Tallman MS, Raisch DW, Smith SW, Silver S, Murday AS, Armitage JO, Goldsmith D (2012) A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 38(8):783–796CrossRefPubMedPubMedCentral
go back to reference Bezwoda WR, Seymour L, Dansey RD (1995) High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 13(10):2483–2489PubMed Bezwoda WR, Seymour L, Dansey RD (1995) High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 13(10):2483–2489PubMed
go back to reference Bohlius J, Weingart O, Trelle S, Engert A (2006) Cancer-related anemia and recombinant human erythropoietin--an updated overview. Nat Clin Pract Oncol 3(3):152–164CrossRefPubMed Bohlius J, Weingart O, Trelle S, Engert A (2006) Cancer-related anemia and recombinant human erythropoietin--an updated overview. Nat Clin Pract Oncol 3(3):152–164CrossRefPubMed
go back to reference Boogaerts M, Coiffier B, Kainz C (2003) Epoetin beta QOL Working Group. Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 88(7):988–995CrossRefPubMedPubMedCentral Boogaerts M, Coiffier B, Kainz C (2003) Epoetin beta QOL Working Group. Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 88(7):988–995CrossRefPubMedPubMedCentral
go back to reference Cantrell LA, Westin SN, Van Le L (2011) The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival. Cancer 117(6):1220–1226CrossRefPubMed Cantrell LA, Westin SN, Van Le L (2011) The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival. Cancer 117(6):1220–1226CrossRefPubMed
go back to reference Chavez-MacGregor M, Zhao H, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH (2011) Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study. Cancer 117(16):3641–3649CrossRefPubMedPubMedCentral Chavez-MacGregor M, Zhao H, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH (2011) Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study. Cancer 117(16):3641–3649CrossRefPubMedPubMedCentral
go back to reference Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16(10):3412–3425PubMed Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16(10):3412–3425PubMed
go back to reference Durmaz O, Demirkaya M, Sevinir B (2011) Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients. Pediatr Hematol Oncol 28(6):461–468CrossRefPubMed Durmaz O, Demirkaya M, Sevinir B (2011) Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients. Pediatr Hematol Oncol 28(6):461–468CrossRefPubMed
go back to reference Engert A (2000) Recombinant human erythropoietin as an alternative to blood transfusion in cancer-related anaemia. Dis Manag Health Outcome 8:259–272CrossRef Engert A (2000) Recombinant human erythropoietin as an alternative to blood transfusion in cancer-related anaemia. Dis Manag Health Outcome 8:259–272CrossRef
go back to reference Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15(3):1218–1234PubMed Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15(3):1218–1234PubMed
go back to reference Kelada O, Marignol L (2014) Erythropoietin-stimulating agents and clinical outcomes in metastatic breast cancer patients with chemotherapy-induced anemia: a closed debate? Tumour Biol 35(6):5095–5100CrossRefPubMed Kelada O, Marignol L (2014) Erythropoietin-stimulating agents and clinical outcomes in metastatic breast cancer patients with chemotherapy-induced anemia: a closed debate? Tumour Biol 35(6):5095–5100CrossRefPubMed
go back to reference Ludwig H, Fritz E, Leitgeb C, Krainer M, Kührer I, Sagaster P, Umek H (1993) Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 4(2):161–167PubMed Ludwig H, Fritz E, Leitgeb C, Krainer M, Kührer I, Sagaster P, Umek H (1993) Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 4(2):161–167PubMed
go back to reference Ludwig H (1999) Epoetin in cancer-related anemia. Nephrol Dial Transplant 14(suppl 2):S 85–S 92CrossRef Ludwig H (1999) Epoetin in cancer-related anemia. Nephrol Dial Transplant 14(suppl 2):S 85–S 92CrossRef
go back to reference Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322(24):1689–1692CrossRefPubMed Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322(24):1689–1692CrossRefPubMed
go back to reference Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D, Epoetin Beta Hematology Study Group (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 20(10):2486–2494CrossRefPubMed Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D, Epoetin Beta Hematology Study Group (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 20(10):2486–2494CrossRefPubMed
go back to reference Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS, American Society of Clinical Oncology, American Society of Hematology (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20(19):4083–4107CrossRefPubMed Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS, American Society of Clinical Oncology, American Society of Hematology (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20(19):4083–4107CrossRefPubMed
go back to reference Sazama K (1990) Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 30(7):583–590CrossRefPubMed Sazama K (1990) Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 30(7):583–590CrossRefPubMed
go back to reference Thomaidis T, Weinmann A, Sprinzl M, Kanzler S, Raedle J, Ebert M, Schimanski CC, Galle PR, Hoehler T, Moehler M (2014) Upper-GI-Group of AIO (Arbeitsgemeinschaft Internistische Onkologie), Germany. Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients. Int J Clin Oncol 19(2):288–296CrossRefPubMed Thomaidis T, Weinmann A, Sprinzl M, Kanzler S, Raedle J, Ebert M, Schimanski CC, Galle PR, Hoehler T, Moehler M (2014) Upper-GI-Group of AIO (Arbeitsgemeinschaft Internistische Onkologie), Germany. Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients. Int J Clin Oncol 19(2):288–296CrossRefPubMed
go back to reference Voravud N, Sriuranpong V (2005) Clinical benefits of epoetin alfa (Eprex) 10000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy. J Med Assoc Thai 88:607–612PubMed Voravud N, Sriuranpong V (2005) Clinical benefits of epoetin alfa (Eprex) 10000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy. J Med Assoc Thai 88:607–612PubMed
Metadata
Title
Efficacy and safety of a biogeneric recombinant human erythropoietin in the management of chemotherapy-induced anemia: a randomized double-blind active-comparator trial
Authors
Yunes Panahi
Alireza Saadat
Saber Imani
Amirhossein Sahebkar
Publication date
01-01-2016
Publisher
Springer London
Published in
Comparative Clinical Pathology / Issue 1/2016
Print ISSN: 1618-5641
Electronic ISSN: 1618-565X
DOI
https://doi.org/10.1007/s00580-015-2158-0

Other articles of this Issue 1/2016

Comparative Clinical Pathology 1/2016 Go to the issue